Opto Circuits' arm launches new drug eluting stent

The launch follows approval from the Drug Controller General of India (DCGI) to sell and market the product in India

Opto Eurocor Healthcare Limited. (OEHL) a subsidiary of Bangalore-based medical devices maker Opto Circuits (India) Ltd.has launched its first Sirolimus Drug Eluting (DES), E-MAGIC® Plus.

The launch follows approval from the Drug Controller General of India (DCGI) to sell and market the product in India. With the launch of E-MAGIC® Plus, Opto Circuits has become one of the few global players to offer DES products with a choice of two drug coatings. The Sirolimus DES market is estimated to be worth Rs 800 crore annually in India.

E-MAGIC® Plus consists of a balloon-expandable intra coronary cobalt chromium stent pre-mounted on a custom balloon delivery system with a Sirolimus coating and a biodegradable polymer. The E-MAGIC® Plus stent releases a distinctive anti-rejection drug, Sirolimus (also known as Rapamycin), into the arterial wall. Sirolimus helps control excess growth of cells and allows the artery to heal. The stent has an extra edge with soft tip technology to provide smooth access to the lesion site ensuring minimal trauma to the vessel wall.   
 
A stent is a wire metal mesh tube that is used to prop open an occluded artery during an angioplasty. Some stents are coated with a drug, which is released into the wall of the artery to help minimize re-narrowing (restenosis) and the growth of scar tissues.

The DES market has two major drug categories: Sirolimus and Paclitaxel. Stents coated with Sirolimus & its derivatives are rapidly gaining market share thanks to the potent immunosuppressive nature of the drug and its comparative effectiveness in treating difficult lesions.

In India, Sirolimus-based angioplasty devices have a more than 90% market share.
 
Vinod Ramnani, Chairman & Managing Director, Opto Circuits (India) Ltd., “E-MAGIC® Plus has been developed indigenously in India and with the mark we can market and sell in India. The DCGI approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East. We trust that E-MAGIC® Plus will offer better treatment options and significant therapeutic advantages for the patients.”

image
Business Standard
177 22
Business Standard

Opto Circuits' arm launches new drug eluting stent

The launch follows approval from the Drug Controller General of India (DCGI) to sell and market the product in India

BS Reporter  |  Bangalore 



Opto Eurocor Healthcare Limited. (OEHL) a subsidiary of Bangalore-based medical devices maker Opto Circuits (India) Ltd.has launched its first Sirolimus Drug Eluting (DES), E-MAGIC® Plus.

The launch follows approval from the Drug Controller General of India (DCGI) to sell and market the product in India. With the launch of E-MAGIC® Plus, Opto Circuits has become one of the few global players to offer DES products with a choice of two drug coatings. The Sirolimus DES market is estimated to be worth Rs 800 crore annually in India.

E-MAGIC® Plus consists of a balloon-expandable intra coronary cobalt chromium stent pre-mounted on a custom balloon delivery system with a Sirolimus coating and a biodegradable polymer. The E-MAGIC® Plus stent releases a distinctive anti-rejection drug, Sirolimus (also known as Rapamycin), into the arterial wall. Sirolimus helps control excess growth of cells and allows the artery to heal. The stent has an extra edge with soft tip technology to provide smooth access to the lesion site ensuring minimal trauma to the vessel wall.   
 
A stent is a wire metal mesh tube that is used to prop open an occluded artery during an angioplasty. Some stents are coated with a drug, which is released into the wall of the artery to help minimize re-narrowing (restenosis) and the growth of scar tissues.



The DES market has two major drug categories: Sirolimus and Paclitaxel. Stents coated with Sirolimus & its derivatives are rapidly gaining market share thanks to the potent immunosuppressive nature of the drug and its comparative effectiveness in treating difficult lesions.

In India, Sirolimus-based angioplasty devices have a more than 90% market share.
 
Vinod Ramnani, Chairman & Managing Director, Opto Circuits (India) Ltd., “E-MAGIC® Plus has been developed indigenously in India and with the mark we can market and sell in India. The DCGI approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East. We trust that E-MAGIC® Plus will offer better treatment options and significant therapeutic advantages for the patients.”

RECOMMENDED FOR YOU

Opto Circuits' arm launches new drug eluting stent

The launch follows approval from the Drug Controller General of India (DCGI) to sell and market the product in India

Opto Eurocor Healthcare Limited. (OEHL) a subsidiary of Bangalore-based medical devices maker Opto Circuits (India) Ltd.has launched its first Sirolimus Drug Eluting Stent (DES), E-MAGIC® Plus.

Opto Eurocor Healthcare Limited. (OEHL) a subsidiary of Bangalore-based medical devices maker Opto Circuits (India) Ltd.has launched its first Sirolimus Drug Eluting (DES), E-MAGIC® Plus.

The launch follows approval from the Drug Controller General of India (DCGI) to sell and market the product in India. With the launch of E-MAGIC® Plus, Opto Circuits has become one of the few global players to offer DES products with a choice of two drug coatings. The Sirolimus DES market is estimated to be worth Rs 800 crore annually in India.

E-MAGIC® Plus consists of a balloon-expandable intra coronary cobalt chromium stent pre-mounted on a custom balloon delivery system with a Sirolimus coating and a biodegradable polymer. The E-MAGIC® Plus stent releases a distinctive anti-rejection drug, Sirolimus (also known as Rapamycin), into the arterial wall. Sirolimus helps control excess growth of cells and allows the artery to heal. The stent has an extra edge with soft tip technology to provide smooth access to the lesion site ensuring minimal trauma to the vessel wall.   
 
A stent is a wire metal mesh tube that is used to prop open an occluded artery during an angioplasty. Some stents are coated with a drug, which is released into the wall of the artery to help minimize re-narrowing (restenosis) and the growth of scar tissues.

The DES market has two major drug categories: Sirolimus and Paclitaxel. Stents coated with Sirolimus & its derivatives are rapidly gaining market share thanks to the potent immunosuppressive nature of the drug and its comparative effectiveness in treating difficult lesions.

In India, Sirolimus-based angioplasty devices have a more than 90% market share.
 
Vinod Ramnani, Chairman & Managing Director, Opto Circuits (India) Ltd., “E-MAGIC® Plus has been developed indigenously in India and with the mark we can market and sell in India. The DCGI approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East. We trust that E-MAGIC® Plus will offer better treatment options and significant therapeutic advantages for the patients.”

image
Business Standard
177 22
Widgets Magazine

More News

  • Star TV Advertisers pay IPL-like rates for India-West Indies T20
  • We focused on creating value, not valuation: Bhavin Turakhia We focused on creating value, not valuation: Bhavin Turakhia
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard